Article
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2012
Pietanza M Catherine, Lynch Thomas James, Lara Primo N, Cho John, Yanagihara Ronald H, Vrindavanam Nandagopal, Chowhan Naveed Mahfooz, Gadgeel Shirish M, Pennell Nathan A, Funke Roel, Mitchell Ben, Wakelee Heather A, Miller Vincent A
Abstract excerpt
INTRODUCTION: Although patients with non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) activating mutations commonly experience significant regressions when treated with erlotinib or gefitinib, they uniformly develop resistance to these agents. The secondary EGFR T790M mutation is found in 50% of patients with acquired resistance. Herein, we studied XL647, an oral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.